The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-Ifn-Α 2a in HBeAgpositive CHB Patients

Infection International
doi 10.1515/ii-2017-0053
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Walter de Gruyter GmbH

Related search

Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV Co-Infected Patients: Implications for Treatment Outcomes

Journal of Hepatology
Hepatology
2010English

Polymorphisms of CYP27B1 Are Associated With IFN Efficacy in HBeAg-positive Patients

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2018English

Baltic Post-Marketing Study of Pegilated Interferon Α-2a 40 KD Efficacy and Safety in Patients With HBeAg–Positive and HBeAg – Negative Chronic Hepatitis B

Virology & Mycology
2013English

Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Theoretical Study on Pegylation Reaction Mechanisms of IFN-α-2a, IFN-α-2b and IFN-β-1a

Journal of the Serbian Chemical Society
Chemistry
2017English

SVR Rates of HCV-infected Population Under PEG-IFN-α/R Treatment in Northwest China

Virology Journal
VirologyInfectious Diseases
2017English

The Clinical Significance of Quantitative HBSAG in Patients With HBEAG Negative Chronic Hepatitis B

Acta Medica Saliniana
Medicine
2019English

Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase Α Inhibitors

ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY
2019English

Predictive Value of Serum IFN-γ Inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy